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Abstract 21 
The discovery of microRNAs (miRNAs) and their critical role in genetic control opened new 22 
avenues in understanding of various biological processes including immune cell lineage 23 
commitment, differentiation, proliferation and apoptosis. However, a given miRNA may have 24 
hundreds of different mRNA targets and a target might be regulated by multiple miRNAs, 25 
thus the characterisation of dysregulated miRNA expression profiles could give a better 26 
insight into the development of immunological disturbances in autoimmune diseases. The aim 27 
of our study was to examine the changes in miRNA expression profiles in patients with 28 
systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Eight SLE 29 
patients, 8 pSS patients and 7 healthy subjects were enrolled in the investigation. MiRNAs 30 
were isolated from peripheral blood mononuclear cells, and expression patterns were 31 
determined with Illumina next-generation sequencing technology. Since the 32 
immunopathogenesis of pSS and SLE encompasses pronounced B cell hyperactivity along 33 
with specific autoantibody production, we paid a special attention on the association between 34 
miRNA expression levels and altered peripheral B cell distribution. In SLE patients 135, while 35 
in pSS patients 26 miRNAs showed altered expression. Interestingly, the 25 miRNAs 36 
including miR-146a, miR-16 and miR-21, which were over-expressed in pSS patients, were 37 
found to be elevated in SLE group, as well. On the contrary, we observed the down-regulation 38 
of miR-150-5p, which is a novel and unique finding in pSS. Levels of several miRNAs 39 
over-expressed in SLE, were not changed in pSS, such as miR-148a-3p, miR-152, miR-155, 40 
miR-223, miR-224, miR-326 and miR-342. Expression levels of miR-223-5p, miR-150-5p, 41 
miR-155-5p and miR-342-3p, which miRNAs are potentially linked to B cell functions, 42 
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showed associations with the B cell proportions within peripheral blood mononuclear cells. The 43 
observed differences in miRNA expression profiles and the better understanding of immune 44 
regulatory mechanisms of miRNAs may help to elucidate the pathogenesis of SLE and pSS. 45 
 46 
47 
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Introduction 48 
 49 
The discovery of microRNAs (miRNAs) and their critical role in genetic control opened 50 
new avenues in understanding of the intricate interplay of inherited and acquired factors 51 
leading to disease development. MiRNAs are single-stranded, endogenous non-coding RNAs, 52 
ranging from 18 to 25 nucleotides in length [1,2]. After the first study revealing the 53 
posttranscriptional regulatory role of non-coding RNAs on gene expression in Caenorhabditis 54 
elegans [3], small RNAs with similar functions were identified in other animal models, such 55 
as Drosophila and zebrafish [4]. Since then, several studies on miRNAs were reported in both 56 
animal models and humans, which shed light on their biology and mechanism of action. It is 57 
already known that mature miRNAs interact with specific messenger (m)RNAs to regulate 58 
gene expression. Target mRNA is recognized by the 2–7 nucleotides of the so called ‘seed’ 59 
region of miRNAs [5]. When the complementary base pairing is perfect or near-perfect, 60 
endonucleotic cleavage is induced, which leads to the degradation of mRNAs. When the base 61 
pairing is incomplete, the formation of double-stranded RNAs resulting from the binding of 62 
miRNAs, leads to translational repression [6,7]. MiRNAs regulate approximately 90% of 63 
protein-coding genes, and play a central role in various biological processes including 64 
immune cell lineage commitment, differentiation, proliferation, apoptosis and maintenance of 65 
immune homeostasis [8]. Alterations in miRNA regulation seem to be highly related to the 66 
development of immune dysfunctions and autoimmunity. In the last years, changes in miRNA 67 
expression have been identified in certain autoimmune diseases including rheumatoid arthritis 68 
(RA), systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS), as well 69 
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[9,10]. Consequently, these molecules may be regarded as novel and attractive biomarkers 70 
specific for different autoimmune disorders; moreover, it has been also suggested that 71 
miRNA-targeting treatment might be more selective than the other therapeutic regiments in 72 
autoimmune diseases [11]. However, it has to be taken into consideration that a 73 
given miRNA may have hundreds of different mRNA targets, and a given target might be 74 
regulated by multiple miRNAs, thus, the intricate interplay between specific miRNAs and the 75 
functionally targeted genes is not elucidated yet. Additionally, genome-wide surveys 76 
identified many single nucleotide polymorphisms (SNPs) in the predicted miRNA target sites, 77 
as well as in miRNAs themselves [11]. In some instances, SNPs have been shown to alter 78 
miRNA function, thus possibly contributing to disease development. The better understanding 79 
of the immune regulatory mechanisms of miRNAs by pathway-based exploratory analyses 80 
and the mapping and characterization of miRNA SNPs may help not only to elucidate the 81 
pathogenesis of autoimmune conditions but also can lead to the development of complex 82 
therapeutic approaches in patients with immunological disorders. 83 
Systemic lupus erythematosus is a clinically heterogeneous, chronic systemic 84 
autoimmune disease characterized by the presence of autoantibodies directed against nuclear 85 
antigens and damage of multiple organ systems, including renal, cardiovascular, 86 
musculoskeletal neural and cutaneous systems. SLE is a relapsing and remitting disease, 87 
encompassing mild to moderate forms, and also severe, progressive variants with a potentially 88 
debilitating, even fatal outcome [12]. Primary Sjögren’s syndrome is a common systemic 89 
autoimmune disease that affects primarily the exocrine glands, leading to decreased lachrymal 90 
and salivary secretion. Besides the characteristic glandular symptoms, other systemic 91 
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symptoms, denoted as extraglandular manifestations (EGM), can also be found in a subset of 92 
patients [13]. The immunopathogenesis of both pSS and SLE are not fully elucidated yet; 93 
albeit enhanced B cell activity and pronounced autoantibody production are the hallmark of 94 
these diseases. 95 
The aim of our study was to examine miRNA expression profiles in patients with pSS and 96 
SLE in order to remark the associations between the dysregulated miRNAs’ expression and 97 
the development of the diseases. Since the immunopathogenesis of pSS and SLE 98 
characterised by pronounced B cell hyperactivity along with specific autoantibody 99 
production, we paid a special attention on the association between miRNA expression levels 100 
and altered peripheral B cell distribution. Additionally, contrary to microarray analysis, the 101 
RNA sequencing technique gave us an opportunity to detect and recognise miRNAs with 102 
SNPs, as well. 103 
 104 
Materials and methods 105 
 106 
Patients and healthy individuals 107 
Eight female patients with pSS (mean age: 55.12 ± 7.49 years, range from 42 to 64 years) and 108 
8 female patients with SLE (mean age: 45.88 ± 10.58 years, range from 36 to 66 years) were 109 
enrolled in the study. All patients were recruited from the Outpatient Clinic for systemic 110 
autoimmune diseases at the Division of Clinical Immunology, University of Debrecen, where 111 
they received regular follow-up treatment. The recruitment of participants was between 112 
14-12-2015 and 29-02-2016. The average disease duration was 13.40 ± 7.94 years in pSS, 113 
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while 14.14 ± 9.14 years in case of SLE. The diagnosis of pSS was based on the 114 
European-American consensus criteria [14]. Among pSS patients, 4 suffered from EGMs, 115 
while 4 had only glandular symptoms. The distribution of EGMs of pSS patients were as 116 
follows: polyarthritis n = 4, Raynaud’s phenomenon n = 3, vasculitis n = 1. The exclusion 117 
criteria included therapy with immunosuppressive/immunomodulatory agents. Vasculitis or 118 
other EGMs needing immunosuppressive treatment were newly recognised. Patients with 119 
SLE fulfilled the corresponding diagnostic criteria for lupus [15,16]. All of the SLE patients 120 
received per os methylprednisolone therapy with an average dose of 4 mg daily; the dose of the 121 
treatment did not exceed 8 mg methylprednisolone per day in any case of SLE patients. The 122 
blood samples were collected from SLE patients 24 hours after taking the regular 123 
methylprednisolone medication. We assessed the actual disease activity of SLE patients and 124 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were calculated. 125 
None of the lupus patients showed clinical activity or had SLEDAI score higher than 4. The 126 
control group consisted of seven age-matched (mean age: 49.78 ± 7.31 years, range from 39 127 
to 61 years) healthy female volunteers. No patients or controls enrolled in this study had 128 
ongoing infections, either viral or bacterial. Table 1 summarizes the demographic and clinical 129 
data of the individuals included in the study. Informed written consent was obtained from all 130 
subjects enrolled in the investigation, and the study has been approved by the Ethics 131 
Committee of our University and the Policy Administration Services of Public Health of the 132 
Government Office (protocol number: IF-13052-9/2015). All experiments carried out were in 133 
compliance with the Declaration of Helsinki. 134 
Table 1. The demographic and clinical data of study individuals. 135 
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pSS patients SLE patients Healthy controls 
Number 8 8 7 
Age in years, mean ± 
SD [range] 
55.12 ± 7.49 [42 - 
64] 
45.88 ± 10.58 [36 - 
66] 
49.78 ± 7.31 [39 - 
61] 
Gender, male/female 0/8 0/8 0/7 
Disease duration in years 
mean ± SD [range] 
13.40 ± 7.94 
[3-22] 
14.14 ± 9.14  
[2-32] 
n.a. 
Extraglandular 
involvement, n (%) 
4 (50) n.a. n.a. 
SLEDAI score n.a 1.75 ± 1.67 [0 - 4] n.a. 
pSS, primary Sjögren's syndrome; SLE, systemic lupus erythematosus; SD, standard 136 
deviation; SLEDAI, systemic lupus erythematosus disease activity index 137 
 138 
 139 
Sample handling 140 
Peripheral blood samples obtained from each study subjects were collected and 141 
mononuclear leukocytes (PBMCs) were separated by Ficoll-Histopaque (Sigma-Aldrich, St 142 
Louis, MO, USA) density-gradient centrifugation.  143 
 144 
RNA isolation 145 
RNA samples were isolated from PBMCs using Trizol reagent (MRC, Cincinnati, Ohio, 146 
USA) according to manufacturer’s protocol. RNA quantity was measured by UV photometry 147 
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using NanoDrop instrument (Themo Fisher Scientific, Waltham, MA, USA). RNA quality 148 
was checked by Agilent BioAnalyzer and RNA samples with RIN > 7 were used for the 149 
further applications. 150 
 151 
RNA sequencing (small RNA-Seq) library preparation 152 
Sequencing libraries for small RNA-Seq were generated from 1 µg total RNA using 153 
TruSeq Small RNA Sample Preparation Kit (Illumina, San Diego, CA, USA) according to the 154 
manufacturer’s protocol. Fragment size distribution and molarity of libraries were checked on 155 
Agilent BioAnalyzer DNA1000 chip (Agilent Technologies, Santa Clara, CA, USA). 156 
Subsequently single read 50 bp sequencing run was performed on Illumina HiScan SQ 157 
instrument (Illumina, San Diego, CA, USA). 158 
 159 
Determination of B cell subsets 160 
For the identification of different lymphocyte subpopulations, PBMCs were stained then 161 
assessed using flow cytometer, as described previously [17]. For identification of B cell 162 
subsets, we used the combination of IgD-fluorescein isothiocyanate 163 
(FITC)/CD27-phycoerythrin (PE)/CD19-phycoerythrin-Cyanine dye 5 (PE-Cy5) (Beckman 164 
Coulter Inc, Fullerton, CA, USA and Immunotech, Marseille, France) and 165 
CD38-FITC/CD27-PE/CD19-PE-Cy5/CD24-allophycocyanin (APC) (BD Biosciences, San 166 
Diego, CA, USA and Beckmann Coulter and BioLegend, San Diego, CA, USA). According 167 
to the expression of IgD, CD27, CD38 and CD24 cell surface markers, the following B cell 168 
subsets were identified: CD19+IgD+CD27- naive B cells, CD19+IgD+CD27+ non-switched 169 
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IgM memory B cells, CD19+IgD-CD27+ switched memory B cells, CD19+IgD-CD27- double 170 
negative (DN) B cells, CD19+CD38-CD24hiCD27+ primarily memory B cells, 171 
CD19+CD38hiCD24hiCD27- transitional B cells, CD19+CD38+CD24+ mature-naive B cells 172 
and CD19+CD38hiCD27hi plasmablasts. Cells were quantified as their percentage in the 173 
CD19+ lymphocyte population. Fluorescence Minus One controls were used in all procedures. 174 
The stained cells were measured by FACS Calibur flow cytometer (Becton Dickinson, 175 
Franklin Lakes, NJ, USA) and data was analysed using FlowJo Software (Treestar, Ashland, 176 
OR, USA).  177 
 178 
Data analysis 179 
CASAVA software was used for pass filtering and demultiplexing process. Sequenced 180 
reads were aligned to Human Genome v19 and bam files were generated. Further statistical 181 
analyses were executed using StrandNGS software (Agilent Technologies, Santa Clara, CA, 182 
USA). Relative small RNA expression levels were calculated using DESeq algorithm. To find 183 
differentially expressed small RNAs between clinical conditions ANOVA analysis with 184 
Tukey post hoc test was performed. 185 
To assess the distribution of the data Shapiro-Wilk normality test and 186 
Kolmogorov-Smirnov test were used. The correlations between two variables were evaluated 187 
with Pearson's correlation coefficient, while in cases of non-normal distribution, Spearman's 188 
test was used. Differences were considered statistically significant at p < 0.05. 189 
 190 
Results 191 
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 192 
We carried out analysis of variance (ANOVA) together with Tukey’s honest significant 193 
difference (HSD) test to evaluate the different expression patterns of miRNAs. We observed 194 
significant differences in the following cases: 25 different miRNAs were up-regulated and 195 
one miRNA was down-regulated in pSS patients compared to controls, while 135 miRNAs 196 
were over-expressed in SLE patients compared to healthy individuals. 197 
Among all 135 significantly up-regulated miRNAs in SLE patients, 113 were over 2 fold 198 
change compared to controls. From those, let-7e-5p, miR-144-5p (11 fold change), 199 
miR-145-5p, miR-190a, miR-345-5p, miR-409-3p and miR-425-3p shown more than 5 fold 200 
change in patients group compared to healthy controls (Figs 1 A and B). 201 
 202 
Fig 1. Fold changes of microRNAs in SLE patients compared to controls. MicroRNAs 203 
(miRNAs) were analysed with Illumina next-generation sequencing technology in SLE 204 
patients compared to controls. A total of 135 miRNAs were over-expressed and 113 miRNAs 205 
of them showed more than 2-fold difference. Particularly, miR-144-5p, let-7e-5p, miR-145-5p, 206 
miR-190a, miR-345-5p, miR-409-3p and miR-425-3p show more than 5-fold change in 207 
patient group compared to healthy controls. 208 
 209 
In pSS group, 25 miRNAs were significantly over-expressed in pSS compared to controls. 210 
Fourteen of them, namely, let-7e-5p, miR-16-1-3p, miR-20b-5p, miR-424-3p, miR-106a-5p, 211 
miR-15a-5p, miR-190a, miR-769-5p, miR-18a-5p, miR-21-3p, miR-145-5p, miR-425-3p, 212 
miR-34a-5p, miR-144-5p showed more than 2 fold change. Of note, all of these miRNAs were 213 
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found to be elevated in the SLE group, as well. On the contrary, miR-150-5p was significantly 214 
down-regulated in pSS (Figs 2 A and B). 215 
 216 
Fig 2. Fold changes of microRNAs in pSS and SLE patients compared to controls. (A) A 217 
total of 26 microRNAs (miRNAs) showed altered expression levels in patients with pSS 218 
compared to controls; among them, 14 miRNAs displayed more than 2-fold change. 219 
Expression of miR-150-5p was down-regulated in pSS. (B) All of these miRNAs were also 220 
analysed in patients with SLE and found to be elevated as well. 221 
 222 
Interestingly, when we compared the miRNA profiles between the subset of pSS patients 223 
with glandular symptoms only and pSS patients with EGMs, we did not find any difference in 224 
miR-150-5p expression between the subgroups of pSS patients. On the contrary, we identified 225 
the over-expression of miR-148a in patients with EGMs, which miRNA did not show any 226 
change in the whole group of pSS patients, compared to the healthy individuals.  227 
Finally, we also carried out the statistical comparison between the miRNA patterns of the 228 
SLE and pSS patients. We have found that 55 miRNAs significantly up-regulated in SLE 229 
compared to pSS. More than half of those have more than 2 fold change (Fig 3). 230 
 231 
Fig 3. Fold changes of microRNAs in SLE patients compared to pSS patients. Fifty-five 232 
microRNAs (miRNAs) were significantly up-regulated in SLE patients compared to pSS 233 
patients. At least half of them have more than 2-fold change. 234 
 235 
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Fig 4 shows the heat map representation [18] of the individual expression levels of certain 236 
miRNAs determined in the PBMCs of SLE and pSS patients and control subjects. 237 
 238 
Fig 4. Expression profile of certain microRNAs in study individuals. Heatmap was 239 
generated using the expression data of 16 miRNAs potentially contribute to autoimmune 240 
disorders. The rows represent the individual miRNAs and columns represent our study 241 
individuals. Elevated expression level was signed by red colour. 242 
 243 
As a next step, we analysed the associations between the expression levels of miRNAs and 244 
the measured B lymphocyte ratios within PBMCs. The miR-223-5p showed a positive 245 
association with naive B cell percentages (R = 0.4859, p = 0.0298), and a negative correlation 246 
with switched memory B cell ratios (R = - 0.5880, p = 0.0064) (Figs 5 A and B).  247 
 248 
Fig 5. Associations between the expression levels of miR-223 and the percentages of 249 
peripheral lymphocyte subsets. The expression levels of miR-223-5p correlated positively 250 
with the proportions of naive B cells (A) and showed a negative correlation with switched 251 
memory B cell percentages (B). Each data point represents an individual subject. Black dots 252 
represents patients, while clear dots with an x show control subjects. 253 
 254 
The miR-150-5p expression levels showed significant positive correlations with the 255 
percentages of DN B cells (R = 0.5523, p = 0.0215) and plasmablasts (R = 0.5409, p = 0.0250) 256 
(Figs 6 A and B). Furthermore, DN B cell ratios also showed significant positive correlations 257 
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with the expression levels of miR-155-5p (R = 0.5410, p = 0.0204) (Fig 6C). Additionally, we 258 
revealed positive correlation between miR-342-3p expression levels and percentages of 259 
plasmablasts, as well (R = 0.5215, p = 0.0265) (Fig 6D). 260 
 261 
Fig 6. Associations between the expression levels of certain microRNAs and the 262 
percentages of peripheral lymphocyte subsets. The expression of miR-150-5p correlated 263 
positively with the ratios of both DN B cells (A) and plasmablasts (B), while other 264 
microRNAs (miRNAs), namely miR-155-5p (C) and miR-342-3p (D) showed positive 265 
associations with DN B cell and plasmablast ratios, respectively. Each data point represents 266 
an individual subject. Black dots represents patients, while clear dots with an x show control 267 
subjects. 268 
 269 
Discussion 270 
 271 
In our study, we revealed moderated alterations in the expression patterns of miRNAs in 272 
patients with pSS. On the contrary, lupus patients showed more pronounced changes in miRNA 273 
expression profile, compared to the results of healthy subjects. Furthermore, the over-expressed 274 
miRNAs in pSS showed elevated expression levels in SLE, as well; although the decreased 275 
expression of miR-150 was observed in pSS patients only.  276 
We compared the expression profiles of pSS and SLE patients in order to get a better 277 
insight into the disease-specific changes in the expression of different miRNAs. In total, 25 278 
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miRNAs were over-expressed in both SLE and pSS, including miR-146a, miR-16 and miR-21. 279 
Consequently, the observed alterations of these miRNAs could be part of the immunological 280 
processes developing in both investigated diseases. The over-expression of miR-146a/b is 281 
induced by LPS-mediated inflammatory responses and leads to translational repression of its 282 
target genes interleukin-1 receptor-associated kinase (IRAK) 1 and tumor necrosis factors 283 
receptor associated factor (TRAF) 6, thus serving as a negative feed-back for immune 284 
activation [19]. In T and B cells, group of miRNAs including miR-21, miR-146a, miR-155 and 285 
others might correlate with epigenetic modifications, support abnormal cytosine release, 286 
differentiation of cell subsets, B cell hyperactivity and autoantibody production [20]. Our 287 
workgroup previously reported the over-expression of miRNA-146 in pSS patients compared 288 
to controls [21]. Regarding SLE, a former study reported the under-expression of miR-146a in 289 
the PBMCs of Chinese SLE patients [22]. Nevertheless, our present study revealed the 290 
over-expression of miR-146a in PBMCs of our SLE patients. This variance between European 291 
and Chinese SLE patients could be explained by the difference in genetic background as well as 292 
various external factors, such as dietary habits, exposure to different infectious agents and other 293 
environmental elements, which may have effects on miRNAs expression [23,24]. The miR-16 294 
is one of the critical regulators of TLR-mediated immune responses, and it can promote NF-kB 295 
regulated transactivation of the interleukin (IL)-8 gene by the suppression of silencing mediator 296 
for retinoid and thyroid hormone receptor (SMRT) [25]. MiR-16 was found to be up-regulated 297 
in patients with RA [26,27], and based on our observations and considering the role of IL-8 in 298 
SLE, the miR-16 could play an important role in lupus as well. MiR-21 is regarded to be one of 299 
the DNA methylation associated miRNAs. It shows higher expression level in PBMCs of SLE 300 
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patients compared to healthy controls [28]. MiR-21 has a pluripotent role in serving to link 301 
distinct lymphocyte signaling pathways and promote B and T cell activation in lupus. Overall, 302 
the elevated miR-21 expression observed in our SLE and pSS patients could be a part of 303 
autoimmune machinery, but presumably the consequence of an initial trigger, and not the 304 
reason. 305 
In the present study, we found several over-expressed miRNAs in SLE, which levels 306 
were not changed in pSS. Hereby, we discuss the significance of miR-148a-3p, miR-152, 307 
miR-155, miR-223, miR-224, miR-326 and miR-342 in details. Over-expression of miR-148a 308 
impaired B cell tolerance by promoting the survival of immature B cells after engagement of 309 
the B cell antigen receptor by suppressing the expression of the autoimmune suppressor 310 
Gadd45α, the tumor suppressor PTEN and the pro-apoptotic protein Bim [29]. In our present 311 
study, we reported the over-expression of miR-148a in SLE; however, we also observed the 312 
same over-expression in pSS patients suffering from EGMs. Taken these together, the 313 
enhanced expression of this miRNA seems to be associated with systemic autoimmune 314 
processes, rather than a specific autoimmune disorder. It was also found that three members 315 
of miR-148 family, including miR-148a, miR-148b and miR-152, are negative regulators of 316 
the innate response and Ag-presenting capacity of DCs [30]. In the present study, the 317 
expression levels of both miR-148a-3p and miR-152 were elevated in the PBMCs of SLE 318 
patients. Beside the aforementioned miRNAs, miR-155 was also elevated in lupus, which is 319 
regarded as a central modulator of immune responses. Activated B and T cells show increased 320 
miR-155 expression, the same goes for macrophages and dendritic cells as well. MiR-155 is 321 
crucial for proper lymphocyte development and maturation and has been shown to be required 322 
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for antibody production. Vigorito et al. reported that B cells lacking miR-155 generate 323 
reduced extrafollicular and germinal center responses and fail to produce high-affinity IgG1 324 
antibodies, and that the transcription factor Pu.1 is a direct target of miR-155-mediated 325 
inhibition [31]. In autoimmune disorders such as rheumatoid arthritis, systemic sclerosis or 326 
psoriasis, miR-155 showed higher expression in patients' PBMCs [11]. In the present study, 327 
we observed enhanced expression of miR-155 in the PBMCs of our adult SLE patients, which 328 
was associated with the increased peripheral DN B cell percentages in lupus. A previous 329 
report proposed that the presence of these cells could be the result of an extrafollicular 330 
differentiation process in secondary lymphoid organs. Their activation does not require T cell 331 
interaction. Furthermore, due to the expression of CXCR3, after receiving activation signals, 332 
DN B cells could migrate to inflamed tissues [32,33]. Taken together, our observations 333 
underline the importance of miR-155 in not only germinal center but also extrafollicular 334 
responses in SLE. We observed elevated miR-223 expression levels in SLE. The present data 335 
on this miRNA is controversial, since it was reported that miR-223 is down-regulated in SLE 336 
patients with active nephritis in Denmark population [34]; while on the contrary, up-regulation 337 
was shown in SLE patients of Asian population [27]. In our study, we revealed the 338 
over-expression of both miR-223-3p and miR-223-5p in our SLE group; additionally, we 339 
demonstrated positive associations with naive B cells, and negative association with switched 340 
memory B cells. These associations are supported by the recent findings showing that the 341 
expression of miR-223 in naive B cells blocks the differentiation of naive B cells into GC B 342 
cells by repressing LIM domain only 2 (LMO2) and MYB Proto-Oncogene Like 1 (MYBL1). 343 
Conversely, a few highly up-regulated miRNAs in naive B cells, such as miR-223, miR-150 344 
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and miR-342-5p, were also down-regulated in activated peripheral blood B cells, suggesting 345 
that they regulate B cell activation [35]. Regarding miR-224, its over-expression facilitates 346 
activation-induced cell death in Jurkat cells. Enhanced expression of miR-224 accelerates T 347 
cell activation-induced cell death by suppressing apoptosis inhibitor (API)5 expression and 348 
associated with LN by enhancing STAT-1 expression in patients with SLE [36]. Our 349 
observation on over-expressed miR-224 in PBMCs underlines its significance in SLE 350 
pathogenesis. Additionally, we found elevated expression levels of miR-326, which was 351 
reported to be over-expressed in PBMCs from type 1 diabetic (T1D) patients with ongoing islet 352 
autoimmunity [37], however, its significance in lupus development needs to be further 353 
clarification. The miR-342-5p, similar to miR-491-5p, has predicted binding sites within the 354 
3′UTR of three genes involved in Wnt signaling [Transcription Factor 7 (TCF7), musashi 355 
RNA-binding protein 1 (MSI1), and paired box 5 (PAX5)]. A recent study indicated that these 356 
miRNAs also participate in the regulation of TCF7, MSI1, and PAX5 genes. PAX5 357 
upregulates lymphoid enhancer-binding factor 1 (LEF1) (TCF7-related protein, regulator of 358 
Wnt signaling) and interacts directly with LEF1 in B cells [38]. In our study, we observed the 359 
significant elevation in both miR-342-5p and miR-491-5p expression; moreover, miR-342-5p 360 
showed a strong positive correlation with plasmablast ratios in SLE. This is an important 361 
result, since PAX5 is one of the key transcription factors for plasma cell differentiation. 362 
We observed the down-regulation of miR-150-5p, which is a novel and unique finding in 363 
pSS. Former studies showed that miR-150-5p might emerge as a master regulator of gene 364 
expression during the immune cells differentiation and immune response process. It plays an 365 
important role in the inhibition of B cell activation and differentiation, and its regulation ability 366 
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in immune cellular process might contribute to the host defence against invading pathogens. 367 
Dysregulated expression of miR-150-5p in immune cells could result in autoimmune diseases 368 
[39]. MiR-150-5p was reported to be over-expressed in autoimmune pancreatitis compared to 369 
chronic pancreatitis, pancreatic cancer and healthy controls [40]. Based on our observations 370 
miR-150-5p is down-regulated in pSS, on the contrary, in SLE patients, miR-150-5p expression 371 
levels were not decreased but elevated, albeit not significantly. We also revealed that 372 
miR-150-5p expression levels associated positively with the percentages of DN B cells and 373 
plasmablasts. Our results are in accordance with the recently reported observations, namely, 374 
DN B cell percentages are lower in pSS, but higher in SLE, while plasmablast ratios are 375 
increased in SLE but not in pSS [17]. Based on these important differences, we assume that the 376 
under-expression of miR-150-5p potentially contributes to the differentiation and activation of 377 
B cells leading to the development of specific autoimmune processes in pSS. 378 
In the present study, we not only depict the alterations in miRNA expression profiles in 379 
SLE and primary Sjögren’s syndrome, but we were the first to compare the changes in miRNA 380 
expression profiles between the two autoimmune diseases at the same time. However, we also 381 
have to mention some limitations of this study. SLE and pSS are clinically heterogeneous 382 
diseases and we worked with a relatively small sample size; therefore, our results should be 383 
confirmed in an independent set of patients. Some of the aforementioned miRNAs may be 384 
regarded as novel biomarkers for the investigated autoimmune disorders; however, functional 385 
experimental studies are also required to verify and establish the causal association between the 386 
aberrantly expressed miRNAs and the development of SLE and pSS. 387 
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In conclusion, the observed differences in miRNA expression profiles in Sjögren’s 388 
syndrome and systemic lupus erythematosus, and the better understanding of the immune 389 
regulatory mechanisms of the relevant miRNAs may help to elucidate the pathogenesis of the 390 
diseases. Certain miRNAs, as potential biomarkers, may not only help in the early diagnosis 391 
and prediction of prognosis, but also could assist in identifying potential targets for therapeutic 392 
interventions in the future. 393 
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